A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System

Br J Haematol. 2018 Jun;181(5):707-710. doi: 10.1111/bjh.14701. Epub 2017 May 3.

Authors

Affiliations

¹ Department of Haematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
² Division of Haematology-Oncology, Department of Medicine, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Korea.
³ Division of Haematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea.

PMID: 28466549
DOI: 10.1111/bjh.14701

No abstract available

Keywords: multiple myeloma; prognosis; risk factors.

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Disease-Free Survival
Female
Follow-Up Studies
Humans
Male
Middle Aged
Multiple Myeloma* / diagnosis
Multiple Myeloma* / mortality
Multiple Myeloma* / pathology
Neoplasm Staging
Predictive Value of Tests
Retrospective Studies
Survival Rate